Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: Results of a double-blind, randomised study

Annals of the Rheumatic Diseases

Volumn 70, Issue 7, 2011, Pages 1264-1271

  Schlesinger, Naomi ^a   Mysler, Eduardo ^b   Lin, Hsiao Yi ^c   De Meulemeester, Marc ^d   Rovensky, Jozef ^e   Arulmani, Udayasankar ^f   Balfour, Alison ^f   Krammer, Gerhard ^f   Sallstig, Peter ^f   So, Alexander ^g  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Organización Médica de Investigaciones OMI   (Argentina)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d Cabinet de Là Haut   (Belgium)

^e NURCH ^*  (Slovakia)

^f NOVARTIS PHARMA AG   (Switzerland)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CANAKINUMAB; COLCHICINE; PLACEBO;

ACUTE DISEASE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY PRODUCTION; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; CONTROLLED STUDY; CYSTITIS; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR INFECTION; ERYSIPELAS; FEMALE; GANGRENE; GOUT; HUMAN; HYPERTENSION; INFECTION; INFLUENZA; INJECTION SITE REACTION; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK REDUCTION; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUS CONGESTION; TONSILLITIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; ANTIBODIES, MONOCLONAL; ARTHRITIS, GOUTY; C-REACTIVE PROTEIN; COLCHICINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GOUT SUPPRESSANTS; HUMANS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79957646006     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.144063     Document Type: Article

References (34)

1. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis 2002;40:37-42.
2. Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005;64:267-72.
3. Schlesinger N. Diagnosis of gout. Minerva Med 2007;98:759-67. (Pubitemid 351196064)
4. Schlesinger N. Diagnosis of gout: clinical, laboratory, and radiologic findings. Am J Manag Care 2005;11 (15 Suppl): S443-50;quiz S465-8.
5. Keenan RT, O'Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011;124:155-63.
6. Schlesinger N, Thiele RG. The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis 2010;69:1907-12.
7. Becker MA, Schumacher HR, Benjamin KL, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol 2009;36:1041-8.
8. Lee SJ, Hirsch JD, Terkeltaub R, et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford) 2009;48:582-6.
9. Edwards N, Blume S, Pan F, et al. Work productivity loss due to flares in treatment-failure gout. Arthritis Rheum 2008;58:S673.
10. Schlesinger N. Diagnosing and treating gout: a review to aid primary care physicians. Postgrad Med 2010;122:157-61.
11. Schlesinger N, Dalbeth N, Perez-Ruiz F. Gout-what are the treatment options? Expert Opin Pharmacother 2009;10:1319-28.
12. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24. (Pubitemid 44620440)
13. Suresh E. Diagnosis and management of gout: a rational approach. Postgrad Med J 2005;81:572-9. (Pubitemid 41297913)
14. Yamanaka H, Togashi R, Hakoda M, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 1998;431:13-18. (Pubitemid 28236731)
15. Becker MA, Schumacher HR, Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005;52:916-23. (Pubitemid 40372228)
16. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004;51:321-5. (Pubitemid 38725128)
17. Schumacher HR, Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540-8.
18. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31:2429-32. (Pubitemid 39610535)
19. Paulus HE, Schlosstein LH, Godfrey RG, et al. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum 1974;17:609-14.
20. Yu TF, Gutman AB. Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med 1961;55:179-92.
21. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010;12:R63.
22. Becker MA, Schumacher HR, Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61. (Pubitemid 41781828)
23. So A. Developments in the scientific and clinical understanding of gout. Arthritis Res Ther 2008;10:221.
24. Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41. (Pubitemid 43372104)
25. Kim JH, Jin HM, Kim K, et al. The mechanism of osteoclast differentiation induced by IL-1. J Immunol 2009;183:1862-70.
26. Tunyogi-Csapo M, Kis-Toth K, Radacs M, et al. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption. Arthritis Rheum 2008;58:2397-408.
27. Alten R, Gram H, Joosten LA, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008;10:R67.
28. So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010;62:3064-76.
29. Wallace SL, Singer JZ, Duncan GJ, et al. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol 1991;18:264-9.
30. Schumacher HR, Sundy JS, Terkeltaub R, et al. Placebo-controlled study of rilonacept for gout flare prophylaxis during initiation of urate-lowering therapy. ACR 2009: Abstract 1096.
31. Neogi T. Interleukin-1 antagonism in acute gout: is targeting a single cytokine the answer? Arthritis Rheum 2010;62:2845-9.
32. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360:2416-25.
33. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007;46:1372-4.
34. Schumacher HR, Taylor W, Edwards L, et al. Outcome domains for studies of acute and chronic gout. J Rheumatol 2009;36:2342-5.